This is a "landmark study" for cancer immunotherapy and circadian medicine, researcher say ...

NSCLC treatment is stage-dependent, involving surgery, chemotherapy, radiation, immunotherapy, and targeted therapy based on tumor genetics. Molecular profiling is essential for personalized treatment ...

Patients with advanced lung cancer who received immunochemotherapy before 15:00 (3 p.m.) had a more delayed disease ...

The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after ...

Study Highlights the Efficacy of PMC in Suppressing Non-Small Cell Lung Cancer Growth SEOUL, SOUTH KOREA, January 23, 2026 ...

Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary ...

Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

Observational study finds more pathologic nodal upstaging with more nodes sampled ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...